---
schema_version: "secwatch.filing_event.v1"
accession: "0001809519-24-000188"
form_type: "8-K"
ticker: "GDRX"
cik: "0001809519"
company_name: "GoodRx Holdings, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:47:12.107516+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# GoodRx adds IQVIA CFO Bruehlman to board; Bezdek extends contract with no severance

## Summary
- Ronald E. Bruehlman (IQVIA CFO) elected to Board and as Audit & Risk Committee chair, effective Nov 8, 2024.
- Director Julie Bradley resigns Nov 8 due to personal commitments; no disagreement with company.
- Chief Mission Officer Douglas Hirsch ends employment Oct 25; stays on Board as non-employee director.
- Chairman Trevor Bezdek's employment extended through Oct 25, 2025; 2025 cash bonus target 100% of salary; no severance.
- Bruehlman receives $420K RSU (3-year vest) and $132K pro-rated annual RSU; eligible for standard director cash retainers.

## SEC filing metadata
- accession: 0001809519-24-000188
- form_type: 8-K
- ticker: GDRX
- cik: 0001809519
- company_name: GoodRx Holdings, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000188/0001809519-24-000188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000188/gdrx-20241022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001809519-24-000188
- JSON: https://secwatch.observer/filing/0001809519-24-000188.json
- Plain text: https://secwatch.observer/filing/0001809519-24-000188.txt

## Key facts
- Executive change
  Ronald E. Bruehlman was elected as Director at GoodRx Holdings, Inc..
  - Action: elected
  - Role: Director
  source text: On October 25, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ronald E. Bruehlman as a Class III director, effective as of the Effective Date, to fill the vacancy on the Board created by the resignation of Julie Bradley.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000188/0001809519-24-000188-index.htm
- Executive change
  Julie Bradley resigned as Director at GoodRx Holdings, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 22, 2024, Julie Bradley notified GoodRx Holdings, Inc. (the “Company”) of her decision to resign as a member of the Board of Directors of the Company (the “Board”), including from her service on the Board’s Audit and Risk Committee, effective as of November 8, 2024 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000188/0001809519-24-000188-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.